IL326723A - נגזרות של 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine כמעכבי kras g12d לטיפול בסרטן - Google Patents

נגזרות של 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine כמעכבי kras g12d לטיפול בסרטן

Info

Publication number
IL326723A
IL326723A IL326723A IL32672326A IL326723A IL 326723 A IL326723 A IL 326723A IL 326723 A IL326723 A IL 326723A IL 32672326 A IL32672326 A IL 32672326A IL 326723 A IL326723 A IL 326723A
Authority
IL
Israel
Prior art keywords
kras
octan
diazabicyclo
inhibitors
cancer
Prior art date
Application number
IL326723A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL326723A publication Critical patent/IL326723A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326723A 2023-08-22 2024-08-22 נגזרות של 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine כמעכבי kras g12d לטיפול בסרטן IL326723A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23315323 2023-08-22
EP24315092 2024-03-14
PCT/EP2024/073621 WO2025040767A1 (en) 2023-08-22 2024-08-22 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine derivatives as kras g12d inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL326723A true IL326723A (he) 2026-04-01

Family

ID=92503540

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326723A IL326723A (he) 2023-08-22 2024-08-22 נגזרות של 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine כמעכבי kras g12d לטיפול בסרטן

Country Status (8)

Country Link
CN (1) CN121909197A (he)
AR (1) AR133619A1 (he)
AU (1) AU2024329738A1 (he)
CO (1) CO2026001992A2 (he)
IL (1) IL326723A (he)
MX (1) MX2026002130A (he)
TW (1) TW202525817A (he)
WO (1) WO2025040767A1 (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2008072850A1 (en) * 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US10022381B2 (en) * 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
CA3148745A1 (en) 2019-08-29 2021-03-04 Xiaolun Wang Kras g12d inhibitors
WO2022194191A1 (en) * 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
CA3224105A1 (en) 2021-06-30 2023-01-05 Huibing Luo Nitrogen-containing heterocyclic compound, and preparation method therefor, intermediate thereof, and application thereof
JP2024540839A (ja) * 2021-10-05 2024-11-06 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法
EP4442686A4 (en) 2021-12-02 2025-10-22 Abbisko Therapeutics Co Ltd KRAS INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL USE

Also Published As

Publication number Publication date
MX2026002130A (es) 2026-04-01
TW202525817A (zh) 2025-07-01
AR133619A1 (es) 2025-10-15
AU2024329738A1 (en) 2026-04-09
CO2026001992A2 (es) 2026-03-05
WO2025040767A1 (en) 2025-02-27
CN121909197A (zh) 2026-04-21

Similar Documents

Publication Publication Date Title
IL319470A (he) תולדות 4-(8,3-דיאזאביציקלו[1.2.3]אוקטן-3-איל)-7-נפתלן-פירידו[3,4-d]פירימידין כמעכבים של אונקופרוטאין מוטנטי kras(g12d) לטיפול בסרטן
IL280701A (he) תולדות 6-(4-אמינו-3-מתיל-2-אוקסא-8-אזאספירו[4.5]דקאן-8-יל)-3-(3,2-דיכלורופניל)-2-מתילפירימידין-4(h3)-ון ותרכובות קשורות כמעכבי ptpn11 (shp2) לטיפול בסרטן
JOP20220142A1 (ar) مثبطات kras g12c
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
MX2024001824A (es) Compuestos heterociclicos y metodos de uso.
PH12020551692A1 (en) 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
MX2026002130A (es) Derivados de 2-(3,8-diazabiciclo[3.2.1]octan-3-il)-1,3,5-triazina como inhibidores de kras g12d para el tratamiento del cancer
PH12022552787A1 (en) Heteroaromatic macrocyclic ether chemotherapeutic agents
MX2023012060A (es) Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
IN2014KN02886A (he)
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
ATE522509T1 (de) Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
IL290177A (he) תולדות 4,2,1-אוקסאדיאזול-5-און לטיפול בסרטן
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
MX2021007602A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.
HK1244436A1 (zh) 治疗癌症的hsp90抑制剂和pd-1抑制剂的组合疗法
CA3302184A1 (en) 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine derivatives as kras g12d inhibitors for the treatment of cancer
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2021010970A (es) Derivados de heteroarilo, y composicion farmaceutica que los comprende.
MX2020008273A (es) Inhibidores de la cinasa del complejo de activacion transcripcional notch ("nack") y metodos para el uso de los mismos.